Physician profile
Suzanne E Storey
NPI 1346225919
$9,247.17
in general payments reported to CMS, 2019-2025
57 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $696 · 2021: $1,275 · 2022: $1,307 · 2023: $1,835 · 2024: $1,256 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.61 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $807.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $694.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $541.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $511.38 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $462.17 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $461.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $404.59 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $403.83 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.99 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $281.12 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $234.30 | 2019-2023 | |
| Lundbeck LLC | $226.62 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $225.79 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $212.27 | 2021-2025 | Gvoke Hypopen, Keveyis |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.